Q-omics provides the consensus-scored MTCYBP43 profile across patient tissues and cancer cell-line models. MTCYBP43 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MTCYBP43 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, MTCYBP43 RNA expression shows 12,544 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, and LSCC as cancer lineages where MTCYBP43 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP43 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP43 survival associations across molecular data types. MTCYBP43 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP43 RNA expression–survival associations across cancer types. High MTCYBP43 expression shows unfavorable associations in LUAD, MESO, CHOL, KIRC, LUSC and ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MTCYBP43 RNA expression.
This table summarizes MTCYBP43 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP43. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP43 shows lower tumor expression in STAD and higher tumor expression in LUAD and LUSC. The LUAD box plot shows higher MTCYBP43 RNA expression in tumor versus normal tissue (log2 FC = +0.115, t-test p = .038).
This table shows molecular features associated with MTCYBP43 in patient tissues and cancer cell lines. In patient samples, MTCYBP43 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
